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Background: Insulin resistance (IR) is currently considered a crucial cardiovascular (CV) risk factor, which seems to
play a dominant role in the evolution toward cardiac and vascular impairment. Early IR-induced cardiac dysfunction
can be assessed by Doppler-derived myocardial systolic strain rate (SR) index, measured at baseline and after
dobutamine stress echocardiography (DSE).
Methods: Thirty IR patients (HOMA-IR = 7 ± 5.2, age 52.6 ± 2.1 years), and 20 healthy, age and sex matched controls
were studied. IR had been diagnosed in all patients in the 3 months preceding the study. Dobutamine
echocardiography was performed in all subjects to exclude ischemic heart disease, and left ventricular contractile
reserve (LVCR) was then assessed. LVCR was evaluated as an increase in the peak of an average longitudinal SR,
measured in the basal and mid segments of 2 and 4 chamber ventricular walls.
Results: No significant differences between the 2 groups were revealed by baseline echocardiography. In contrast,
after DSE a significant decrease of Delta SR was found in the IR group in comparison to the controls (0.54 ± 0.31 s−1
vs 1.14 ± 0.45 s−1; p < 0.0001).
Conclusions: Our results show that IR, even if isolated and arising within a short time period, not only represents
the initial phase of future diabetes, but may adversely affect heart function, as evidenced by the depressed LVCR.
Our data strengthen the need for attention to be paid to IR state and for an early therapeutic approach.
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Diabetes mellitus has been shown to induce cardiac
contractile dysfunction, which results from metabolic
derangements and may evolve into a specific cardiomy-
opathy [1]. It has also been well established that the on-
set of type 2 diabetes mellitus is preceded by a variable
period of abnormal glucose homeostasis, characterized
by progressive insulin resistance (IR) and impairment of
β-cell function [2].
Individuals with IR are at high risk of adverse cardiovas-
cular events (myocardial infarction, stroke, cardiovascular
death) later in life. A high prevalence of heart failure is
associated with IR [3,4], and epidemiological evidence* Correspondence: cadedduc@unica.it
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reproduction in any medium, provided the orsuggests that the metabolic disorder precedes cardiac
decompensation.
Recently, IR has been shown to predict the subsequent
development of heart failure, regardless of all known risk
factors, including diabetes mellitus [5,6].
On the basis of this evidence, the existence of an
“insulin-resistant cardiomyopathy” has been proposed
[7] and increased interest has been directed to the
specific cellular mechanisms by which this metabolic
disorder can lead to cardiac structural and functional
abnormalities [8].
With regard to the causal relationship between IR and
cardiac function, the availability of epidemiological and
clinical findings are not matched by an equal knowledge of
the underlying mechanisms: alterations in hemodynamics,
plasma volume, neurohormonal status, and myocardialal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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changes [7]. In relation to the high probability that the pre-
diabetic condition can cause myocardial impairment, it
would be extremely valuable to detect early contractile
function changes in subjects affected by IR alone, prior the
development of the metabolic syndrome as well as from
overt cardiovascular disease.
Dobutamine stress echocardiography (DSE), widely
used in patients with coronary artery disease or dilated
cardiomyopathy, enables evaluation of left ventricular
contractile reserve (LVCR) [9]. In particular, the assess-
ment of longitudinal LVCR has proved useful to identify
early myocardial dysfunction in patients with type 2 dia-
betes [10,11].
Based on the hypothesis that IR might be an independ-
ent factor responsible for the development of impaired
systolic function, the LVRC of a population of individuals
<55 years, whose IR had been diagnosed in the 3 months
before the study, was compared to that of a control group
matched for age, gender and body mass index (BMI).
Methods
Thirty-two patients (15 male/17 female), aged <55 years
(52.6 ± 2.1 years), were consecutively selected from a
population of individuals screened at the Diabetic Centre
of our University Hospital and enrolled on the study. All
patients presented impaired glucose tolerance (IGT)
which had been identified within the previous 3 months,
and/or impaired fasting glucose (IFG), and all were
affected by IR, calculated in accordance with the
Homeostasis Model Assessment (HOMA) index and de-
fined according to the values of Bonora et al. [12]. The
patients were referred to our stress echo laboratory as
they reported a family history of ischemic heart disease.
Twenty age, gender and body mass index matched
normoglycemic subjects (HOMA <2.8; 9 male/11 fe-
male), with no structural heart defects or evidence of
ischemic heart disease were also enrolled as controls.
Inclusion criteria for both IR patients and controls
were: age 20–55 years, echocardiographic left ventricular
ejection fraction (LVEF) ≥55% and absence of echocar-
diographic wall motion abnormalities, normal hepatic
and renal function (bilirubin ≤1.5 mg/dl, creatinine
≤2.0 mg/dl). Exclusion criteria were diabetes, smoking,
hypertension with LV hypertrophy, obesity (overweight
was tolerated with a BMI <29.9), moderate to severe
heart valve disease, atrial fibrillation or severe arrhyth-
mias. The presence of dyslipidaemia or hypertension
without left ventricular (LV) hypertrophy was admitted,
provided that only one of these risk factors was present
in any single individual in combination with IR. No
patient was on medication that could influence glucose
metabolism or cardiac function. The present study was
approved by the Ethical Committee of our UniversityHospital and informed written consent was obtained
from all participants.
At enrolment, physical examination, 12-lead electrocar-
diogram, M-mode, 2D and Doppler-echocardiography, and
complete blood chemistry were performed in all subjects.Conventional echocardiography and Tissue Doppler
Imaging (TDI)
All participants were instructed on the medical environ-
ment and instrumentation before testing. Echocardio-
graphic images were recorded using a TDI imaging and
raw data acquisition system (Toshiba Aplio; Toshiba
Corp., Tochigi, Japan). LVEF was obtained from the
apical 4- and 2-chamber views according to Simpson’s
rule and was considered abnormal when <55%. Pulsed
Wave Doppler (PWD) examination was carried out of
the LV inflow from the 4-chamber view with the sample
volume placed between the mitral leaflet tips and the early
(E) and late (A) diastolic peak velocities; E deceleration time
(DecT) was measured and E/A ratio was derived.
Longitudinal function was assessed using pulsed TDI
at mitral annulus, placing the sample volume in the
basal segment of the interventricular septum (IVS) from
the apical 4-chamber view; peak velocities in systole
(Sm), early (Em) and late (Am) diastole were measured.
LV longitudinal function at baseline and after DSE was
evaluated offline from raw data (TDI-Q, Toshiba); longi-
tudinal strain (Σ) and strain rate (SR) (average from
basal and mid segments of 4 chamber and 2 chamber
view) were also quantified based on TDI imaging. All
the examinations on each patient were carried out by a
single experienced echocardiographer. A simultaneous
electrocardiographic trace was also obtained. To reduce
inter-observer variability, all echocardiographic data were
randomly read by a second experienced observer and an
average value for each measurement was calculated. Repro-
ducibility of TDI parameters in our laboratory had been
previously documented [13].DSE
Dobutamine was administered according to standard 3-min
incremental protocol (5 to 40 μg/kg/min), and atropine was
injected in patients who had not achieved 85% of their
maximal heart rate (1 mg, with increments of 0.25 mg until
the target heart rate) [14]. TDI of the 4 and 2 chamber view
was recorded at rest and at peak dose. The 12-lead ECG
(Mortara instruments, inc.) was monitored throughout, and
blood pressure (BP) recorded at rest and at 3-min intervals
during infusion and recovery. End points of the stress
protocol were completion of the protocols, progressive or
severe chest pain, severe ventricular arrhythmias, systolic
BP of 240 mm Hg, diastolic BP of 100 mm Hg, or severe
adverse effects.
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measured off line from raw data. According to the 16-
segment model of the 4 tomographic LV views, regional
wall motion was scored as normal (1), hypokinetic (2),
akinetic (3), and dyskinetic (4), and wall motion score
index (WMSI) was derived by two experienced observers
blinded to the patient’s clinical data.
Statistical analysis
With regards the anthropometric and clinical character-
istics of the two groups, continuous variables were
compared with ANOVA, and categorical variables were
compared with the Fisher’s exact test. Differences in
echocardiographic parameters were also evaluated using
ANOVA. A two-tailed value of p < 0.05 was considered
statistically significant. Data are presented as mean ± SD.
Receiver operating characteristic (ROC) analysis was
used to assess the best cut-off value of Delta SR to
predict myocardial contractile reserve.
A measure of the area under the ROC curve was
calculated. Sensitivity, specificity, and accuracy calcula-
tions were performed according to standard definitions.
The 95% CIs were calculated and the individual intervals
were compared.
Results
Two of the 32 IR patients were excluded from the study
as they were positive for ischemia at DSE. They then
underwent coronary angiography which confirmed sig-
nificant coronary stenosis. The clinical and laboratory
data of the remaining 30 patients and controls are sum-
marized in Table 1. The subjects of both groups were on
average overweight, with IR patients showing a signifi-
cantly higher BMI than controls (28.8 ± 5.5 kg/m2 vs
26 ± 3.5 kg/m2; p < 0.05). None of the investigated
individuals were obese. A HOMA >2.77 as anticipated,Table 1 Clinical and laboratory data
Parameter IR patients Controls p
Age (yrs) 52.6 ± 2.1 51.8 ± 2.0 ns
Weight (kg) 81.3 ± 14 72 ± 14 ns
BMI (kg/m2) 27.3 ± 1.4 26 ± 3.0 <0.05
Waist circumference (cm) 98 ± 6.2 92 ± 5.3 ns
Fasting glucose (mg/dl) 114 ± 13 92 ± 11 <0.01
Homa IR 7 ± 5.2 1.4 ± 0.8 <0.01
Total cholesterol (mg/dl) 204 ± 16 184 ± 26 ns
HDL (mg/dl) 52 ± 11 57 ± 9 ns
LDL (mg/dl) 128 ± 14 117 ± 18 ns
Triglycerides (mg/dl) 149 ± 50 111 ± 38 ns
Smoking None None –
Hypertension (%) no LVH 27% 35% ns
Abbreviations: BMI Body mass index, LVH left ventricle hypertrophy.was a criterion for inclusion in the study for all patients
[12]. Conversely, a HOMA ≤2.77 and fasting glucose
within the normal range was demonstrated in all control
group subjects. No differences were observed between
the two groups of individuals in terms of arterial hyper-
tension with no LV hypertrophy and hyperlipidaemia. In
agreement with the exclusion criteria, no patient or
control subject was affected by both of the 2 risk
factors (Table 1).
All patients and controls showed a normal baseline
ECG, as well as normal LV dimensions, systolic function,
and ventricular mass (Table 2). The baseline longitudinal
systolic function provided by TD imaging (Sm wave)
was also within normal range in both groups. Finally,
longitudinal Σ and SR at rest were comparable in patients
and controls (Table 3).
All participants underwent DSE (see Methods), which
was generally well tolerated. Minor predictable inconve-
niences, such as palpitations and systolic hypotension
occurred, but in no case did discontinuation of the test
result. With regard to the outcome of the pharmaco-
logical stress test, IR patients showed reduced longitu-
dinal SR at the peak of drug administration as compared
to controls (2.45 ± 0.21 sec−1 vs 2.87 ± 0.26 sec−1,
p < 0.0001, Table 3). Moreover, Delta SR between peak
and basal values was significantly reduced in IR patients
when compared with controls (Figure 1; 0.54 ± 0.31 sec−1
vs 1.14 ± 0.45 sec−1, p < 0.0001, Table 3), thereby revealing
reduced LVCR.
Using ROC analysis, a value of 0.85 sec−1 obtained as
a stress–rest difference in the mean value of peak
systolic SR was the best cut-off value to diagnose myo-
cardial contractile reserve [area under the curve 0.879Table 2 Transthoracic conventional echocardiographic
and TDI parameters
Parameter Insulin resistance Controls p
EDD (mm) 47.86 ± 4.56 47.01 ± 5.87 ns
EDV (ml) 80.62 ± 20.20 70.65 ± 4.26 ns
LAA (cm2) 18.63 ± 3.09 18.63 ± 4.32 ns
LVM (g/m2) 63.83 ± 13.27 57.56 ± 11.21 ns
LVEF (%) 66 ± 5.1 65 ± 4.9 ns
E/A ratio 0.92 ± 0.22 1.02 ± 0.27 ns
DecT (sec) 0.22 ± 0.06 0.20 ± 0.04 ns
Sm (cm/sec) 46.9 ± 7.7 52.9 ± 6.2 ns
Em (m/sec) 7.9 ± 1.9 8.2 ± 1.6 ns
E/Em 9.9 ± 2.56 9.8 ± 2.01 ns
Abbreviations: EDD end diastolic diameter, EDV end diastolic volume, LAA left
atrium area, LVM left ventricular mass, LVEF Left Ventricular Ejection Fraction,
E/A early and late diastolic peak velocity ratio, DecT E wave deceleration time,
Sm TD systolic peak velocity, Em TD early diastolic peak velocity, E/E early PWD
and TD diastolic peak velocity ratio.




Σ (%) 23.9 ± 6.13 24.5 ± 8.22
SR (sec−1) 1.74 ± 0.32 1.91 ± 0.29
High dose dobutamine
Σ (%) 26.7 ± 4.32 23.6 ± 5.1
SR (sec−1) 2.87 ± 0.26* 2.45 ± 0.21*
Δ Stress
Σ (%) +2.2 ± 1.8 (+9%) −0.9 ± 1.7 (−4%)
SR (sec−1) 1.14 ± 0.45 (+66%)* 0.54 ± 0.31 (+27%)*
Abbreviations: SR Strain Rate, Σ Strain. *P < 0.0001.
Figure 2 ROC analysis of stress–rest difference in the mean
value of peak systolic SR. [Area under the curve 0.879
(95% CI 0.79–0.97)].
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cificity 70% (95% CI 46–88)] (Figure 2).
There were no changes in the Σ (Table 3), due to the
influence exercised on this parameter by stroke volume,
which tends to be reduced after dobutamine, for the
increase in heart rate and the resulting reduction in
diastolic filling.
Discussion
The present study examined baseline cardiac perform-
ance and LVCR in middle-aged individuals (mean age
52.6 ± 2.1 years) with recent recognition (2.3 ± 0.8 months)
of IR, without diabetes and free from cardiovascular clinical
disease. They were compared with age and gender matched
subjects with normal glucose tolerance. We found that:
i. baseline echocardiography LV mass, dimensions and sys-
tolic function (EF%) were comparable in insulin-resistant
individuals and controls; ii. longitudinal Σ and SR at rest
were similar between the 2 groups; iii. subjects with IR
showed a reduced increase in longitudinal SR values (DeltaFigure 1 SR Delta SR values obtained in patients and in
healthy controls.SR) at DSE in comparison with controls, revealing reduced
LVCR. These results suggest that IR, even shortly after
onset, is associated with cardiac dysfunction, detectable
under conditions of greater functional effort.
IR and myocardial characteristics
The period preceding overt of type 2 diabetes mellitus is
characterized by a state of IR and worsened β-cell
function, which is clearly evident in subjects with IGT
and/or IFG. In turn, IR has been independently associ-
ated with magnetic resonance measures of LV mass and
LV mass to end-diastolic volume ratio, suggesting
involvement in concentric LV remodelling [15]. Abnor-
mal glucose homeostasis was found correlated with
impaired LV diastolic function [16], and this relationship
has been shown to be independent of blood pressure, LV
geometry, total plasma lipids and obesity [17]. In a large
community-based sample, LV mass and wall thickness
increased across categories of worsening glucose toler-
ance [18]. Moreover, cardiometabolic profile and inflam-
mation markers have been shown to be more severely
altered in men and women with both IFG and IGT com-
pared with those with IFG alone. These individuals, in
the absence of hypertension, were seen to have a 10-fold
greater probability of preclinical cardiovascular disease
[19]. IR was also seen to be an independent predictor of
atherosclerosis plaque progression in patients with
coronary heart disease in both the diabetic and non-
diabetic population [20].
Despite these important premises, our IR patients showed
conventional echocardiographic parameters within normal
limits at baseline. In particular, no increase in myocardial
mass was observed, in comparison with controls. The ab-
sence of LV remodelling in these subjects can be ascribed
to the very recent emergence of IR, and that the blood
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trary, it is well documented that long-standing IR, not
countered by any therapeutic measure, is co-responsible for
the development of LV hypertrophy, as well as for myocar-
dial fibrosis, a crucial modification in the pathogenesis of a
cardiomyopathy [21].IR and myocardial energetic metabolism
It is becoming increasingly evident that minor abnormal-
ities occur in the insulin-resistant state that precedes the
manifestation of overt type 2 diabetes, although IR patients
were mostly investigated in the presence of co-morbidities
and/or a long time after the initial diagnosis [7,8]. IR can
lead to myocardial injury by contributing to lipotoxicity,
sympathetic up-regulation, inflammation, oxidative stress,
and fibrosis. The existence of an insulin-resistant cardiomy-
opathy, which is characterized by inefficient energy metab-
olism [7], has been demonstrated in animal models. In
sucrose-fed rats, serial echocardiographic assessments
revealed that early abnormalities in diastolic function,
followed by late systolic dysfunction, were associated with
IR. A concurrent depressed sarcoplasmic reticulum func-
tion was demonstrated by a significant reduction in Ca (2+)
uptake [1].
In the IR patients in this study, both indices of
diastolic function and highly sensitive parameters of in-
trinsic myocardial function, such as longitudinal Σ and
SR, were comparable at rest to those of healthy controls.
As previously stated, this baseline myocardial efficiency
can be attributed to the very recent diagnosis of IR.
Moreover, the relatively young age (less than 55 years) of
our patients, contributed to minimize the effects of
aging on cardiac performance.IR and inotropic reserve
Assuming that patients with recent IR onset are carriers
of an unapparent myocardial dysfunction at baseline
rest, their levels of functional coronary reserve were in-
vestigated by DSE. Indeed, the provocative test revealed
an initial but significant contractile dysfunction in these
subjects, denoted by a smaller inotropic response to
dobutamine in comparison to controls. The presence of
minor changes in systolic performance documents a
functional IR-related cardiomyopathy, distinct from the
diabetic morphological type, characterized by macro-
scopic changes, such as hypertrophy.
The recognition of an early decline of LVCR in
middle-aged individuals with isolated IR of recent onset
is the original aspect of this study. In previous studies
on this topic, older populations were recruited, IR was
accompanied by comorbidities, especially obesity, and,
above all, glucose intolerance was manifested over much
longer time periods [5,7,8,22,23].In a recent study, longitudinal contractile reserve was
found significantly lower in pre-diabetic subjects during
exercise. They were aged 36–76 years, suffered from
Metabolic Syndrome and were hypertensive [24].
Although our results suggest that IR may act via a direct
and independent mechanism, we can only hypothesize the
pathophysiological basis of this effect. At the myocardial
level, insulin inhibits NO production [25]; consequently, an
insufficient response to the hormone may determine re-
duced NO release, with potential endothelial dysfunction.
More recently, IR that has been reported in association
with exercise intolerance in heart failure patients has been
partly attributed to reduced coronary flow reserve [26].
Moreover, alteration of the myocardial energetic metabol-
ism caused by IR can lead to ATP production impairment
[27-30]. This dysfunction may become significant under
conditions of increased energy demand, such as during cat-
echolaminergic stress. These mechanisms, masked in basal
conditions and disclosed by pharmacological stress, should
have resulted in contractile reserve reduction in our IR
individuals.
Conclusions
It is well recognized that IR can contribute to an in-
creased risk of coronary heart disease [30], it is highly
prevalent in non-ischemic heart failure, and it is a com-
mon co-morbidity in congestive heart failure [6], where
IR predicts the development and independently defines a
worse prognosis [7]. In accordance with this clinical evi-
dence, our results recommend the greatest attention be
paid to IR state from its initial appearance and support
an early therapeutic approach to this threatening meta-
bolic defect. We recently showed that early metformin
treatment in IR patients can improve endothelial func-
tion and even cardiopulmonary performance in those
subjects with higher HOMA-IR [31,32].
Moreover, a non-invasive, repeatable assessment of
coronary circulatory dysfunction, like the one employed
in this study, may enable us to monitor myocardial
response to corrective actions with drugs, diet and phys-
ical activity.
Further extensive and prolonged studies are required to
confirm the validity of the approach used in this study as a
tool for image-guided and personalized diabetic preventive
care. Our results show that IR, even if isolated and arising
within a short time period, not only represents the initial
phase of future diabetes, but may adversely affect heart
function, as evidenced by the depressed LVCR. Our data
strengthen the need for attention to be paid to IR state and
for an early therapeutic approach.Abbreviation
IR: Insulin resistance; CV: Cardiovascular; SR: Strain rate; DSE: Dobutamine
stress echocardiography; LVCR: Left ventricular contractile reserve;
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ventricule; LVEF: Left ventricule ejection fraction; PWD: Pulsed wave doppler;
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